Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Myers, B
MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-, in patients with advanced liver cancer: a First-in-Human, Multicenter, Open-Label, Phase I Trial
What they found: Mean weight loss: 2.6 kg vs 2.3 kg placebo , a difference of only 0.3 kg (1 %) Statistically non-significant Clinically unsatisfactory for the obesity indication Safety profile remained favorable Why it matters: The study stopped the development of AOD-9604 as a drug
These IGFBPs transport IGF-1 through the bloodstream but also limit its biological activity
US$ 28.75
US$ 23.41
.jpg)
US$ 20.39
US$ 20.19
US$ 29.86
